Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01940796

Study Title
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) (NCT01940796)

Trial Description
This research study is trying to determine the safest dose of brentuximab vedotin (also known as SGN-035) that can be given to patients with chronic Graft-vs.-Host Disease (GVHD) and see if chronic GVHD improves.

This trial is sponsored by Seattle Genetics/ Massachusetts General Hospital. [1]

Study data

  • Condition: Graft vs. Host Disease (GVHD)
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 40
  • Start: October 2013
  • Estimated Completion: September 2019
  • Last verified: November 2014

Study Schematic

Screen Shot 2016-07-06 at 4.34.24 PM


Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar